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Abstract
Background: The PAX6 protein is a highly conserved transcriptional regulator that is important
for normal ocular and neural development. In humans, heterozygous mutations of the PAX6 gene
cause aniridia (absence of the iris) and related developmental eye diseases. PAX6 mutations are
archived in the Human PAX6 Allelic Variant Database, which currently contains 309 records, 286
of which are mutations in patients with eye malformations.
Results: We examined the records in the Human PAX6 Allelic Variant Database and documented
the frequency of different mutation types, the phenotypes associated with different mutation types,
the contribution of CpG transitions to the PAX6 mutation spectrum, and the distribution of chain-
terminating mutations in the open reading frame. Mutations that introduce a premature
termination codon into the open reading frame are predominantly associated with aniridia; in
contrast, non-aniridia phenotypes are typically associated with missense mutations. Four CpG
dinucleotides in exons 8, 9, 10 and 11 are major mutation hotspots, and transitions at these CpG's
account for over half of all nonsense mutations in the database. Truncating mutations are
distributed throughout the PAX6 coding region, except for the last half of exon 12 and the coding
part of exon 13, where they are completely absent. The absence of truncating mutations in the 3'
part of the coding region is statistically significant and is consistent with the idea that nonsense-
mediated decay acts on PAX6 mutant alleles.
Conclusion: The PAX6 Allelic Variant Database is a valuable resource for studying genotype-
phenotype correlations. The consistent association of truncating mutations with the aniridia
phenotype, and the distribution of truncating mutations in the PAX6 open reading frame, suggests
that nonsense-mediated decay acts on PAX6 mutant alleles.
Background
The PAX6 gene was cloned during the search for genes
underlying the WAGR syndrome (Wilms tumor, aniridia,
genitourinary abnormalities and mental retardation; MIM
194072) [1]. WAGR syndrome is caused by hemizygous
deletions of 11p13 that remove one copy of PAX6 and one
copy of WT1 [1,2]. Intragenic PAX6 mutations were sub-
sequently identified in numerous non-syndromic aniridia
patients, confirming PAX6  as the aniridia gene (MIM
106210) [3-6]. Studies on WAGR patients and aniridia
patients with chromosomal rearrangements clearly dem-
onstrated that aniridia could be caused by deletion of one
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copy of the PAX6 gene [1,2]. Thus it was proposed that
aniridia results from PAX6  haploinsufficiency and is
caused by loss-of-function of one allele [1,5-7].
The PAX6 gene encodes a highly conserved transcriptional
regulatory protein that is expressed in the developing eye,
brain, spinal cord and pancreas [8]. The 5' two-thirds of
the open reading frame (ORF) encode two DNA binding
domains, a paired domain and a homeodomain (Figure
1) [9,10]. The DNA binding domains are separated by a
79-amino acid linker peptide. The 3' third of the ORF
encodes a proline, serine and threonine-rich (PST)
domain that has transcriptional trans-activation function
[11] (Figure 1). The last 40 amino acids of the PST domain
constitute a highly conserved C-terminal peptide that has
been implicated in modulation of DNA binding by the
homeodomain [12].
PAX6 mutations are archived in the Human PAX6 Allelic
Variant Database [13,14]. The database now contains 309
records, each reporting independently ascertained
sequence variations in the PAX6 gene. Two hundred and
eighty-six of these are associated with pathological muta-
tions that cause congenital eye malformations. The most
The PAX6 cDNA and protein Figure 1
The PAX6 cDNA and protein. Top: the PAX6 cDNA is represented as a horizontal rectangle with the different coding regions 
indicated: PB, paired box, LNK, linker region, HB, homeobox, PST, proline/serine/threonine-rich region. Exon boundaries are 
indicated by vertical black lines. 5a is alternatively spliced exon in the paired box. Thick horizontal lines indicate untranslated 
regions (not to scale). Bottom: cartoon of the PAX6 protein showing the different functional domains. N, N-terminus of pro-
tein; C, C-terminus; PB(N), N-terminal subdomain of paired domain; PB(C), C-terminal subdomain of paired domain; HD, 
homeodomain; PST, PSTdomain.
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common of these malformations is aniridia, which is
chiefly characterised by congenital absence of the iris, but
which also affects the cornea, lens and retina. PAX6 muta-
tions also cause a range of non-aniridia phenotypes such
as optic nerve defects, keratitis, microphthalmia, and
foveal hypoplasia [15-17]. This database records allow
analysis of the distribution of mutations in the gene and
the relationship between genotype and phenotype.
Although a comprehensive review of the mutations in the
database has been published previously [18] we wanted
to re-analyse the data for two reasons. First, the last review
was published seven years ago and the number of records
has greatly increased, from 87 to 309. Second, it is instruc-
tive to consider the effect of emerging molecular mecha-
nisms that act on mutant alleles, such as nonsense-
mediated decay. Nonsense-mediated decay (NMD) is the
process by which mRNAs that contain premature termina-
tion codons (PTCs) are degraded before they produce
large quantities of truncated proteins [19,20]. NMD is of
relevance to the PAX6 mutation spectrum because muta-
tions that introduce a PTC into the PAX6 open reading
frame are very common [18]. Before the discovery of
NMD it was widely thought that PTC-containing mutant
alleles generated truncated proteins [5,6]. Some research-
ers speculated that PAX6 proteins truncated after the
homeodomain might have dominant negative activity
[21-23]. The two intact DNA binding domains, divorced
from the normal trans-activation domain, could theoreti-
cally bind to target DNA sequences without activating
downstream genes and could potentially interfere with
the function of the normal PAX6 protein. A variety of
experimental assays showed that PAX6 proteins with C-
terminal deletions do indeed have potent dominant neg-
ative activity [21,22,24]. It might be expected therefore
that truncating mutations after the homeodomain could
potentially lead to phenotypes more severe than, or mark-
edly different from, truncating mutations in the DNA
binding domains. Alternatively, if nonsense-mediated
decay acts on PTC mutations in vivo, all PTC alleles will
effectively be null alleles, and no phenotypic difference
should be observed. This idea can be explored by examin-
ing the records in the PAX6 Allelic Variant Database
In this paper we review the mutations archived in the
PAX6 Allelic Variant Database. We show that over three-
quarters of aniridia cases are caused by mutations that
introduce a PTC into the PAX6 open reading frame. In
contrast, most non-aniridia phenotypes are associated
with missense mutations. We also show that four CpG
dinucleotides are major mutational hotspots, and account
for half of all nonsense mutations in the database. Finally
we attempt to reconcile the observed PAX6 mutation spec-
trum with the work done on truncated PAX6 proteins. We
suggest that the PAX6  mutation spectrum is consistent
with the idea that nonsense-mediated decay is a major
mechanism acting on PAX6 mutant alleles, and conse-
quently that most truncated proteins are unlikely to be
produced at significant levels in vivo. Among the existing
records, there are no truncating mutations in the 3' part of
the coding region where RNA surveillance would not be
predicted to act. This suggests that 3' mutations do in fact
yield dominant negative alleles that may cause severe phe-
notypes, but these have not yet been ascertained.
Results and discussion
Truncating mutations in the PAX6 gene are 
predominantly associated with aniridia
The PAX6 Allelic Variant Database contains 309 records of
which 286 refer to pathological mutations in the PAX6
coding region (exons 4–13, Figure 1) or the consensus
splice sites directly flanking the coding exons. The remain-
ing records describe polymorphisms.
Each of the 286 disease-associated mutations was classi-
fied into one of six categories according to the apparent
effect of each genomic change. The six categories are non-
sense mutations, splicing mutations, frame-shifting inser-
tions or deletions, in-frame insertions or deletions,
missense mutations and run-on mutations. Details of
these are given in Table 1.
Table 1: Categories of mutation in the PAX6 Allelic Variant Database
Category Definition
Nonsense Single nucleotide substitution creates a stop codon in the open reading frame.
Splicing Nucleotide substitution, deletion or insertion in consensus splice site.
Frame-shifting insertion or deletion Deletion or insertion of nucleotides in the open reading frame – total number not divisible by three.
In-frame insertion or deletion Deletion or insertion of nucleotides in the open reading frame – total number divisible by three.
Missense Single nucleotide substitution changes one amino acid codon to another in the open reading frame.
Run-on Nucleotide substitution, insertion or deletion changes the termination codon to an amino acid codon. 
Translation is predicted to continue into the 3'UTR.
Each of the 286 disease-associated mutations in the database was assigned to one of these categories. Twelve compound mutations (each involving 
more than one mutational event) were categorised according to the final consequence of the mutation (see Methods). 3'UTR, 3' untranslated 
region.BMC Genetics 2005, 6:27 http://www.biomedcentral.com/1471-2156/6/27
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The exon-by-exon distribution of mutation type for 286
pathological mutations is shown in Table 2. Of the 286
mutations, 102 (35.7%) are nonsense mutations, 36
(12.6%) are splice mutations, 68 (23.8%) are frame-shift-
ing insertions or deletions, 16 (5.6%) are in-frame inser-
tions or deletions, 50 (17.5%) are missense mutations
and 14 (4.8%) are run-on mutations (Figure 2a).
Nonsense mutations, splice mutations and frame-shifting
insertions or deletions typically result in the introduction
of a PTC into the open reading frame. In the PAX6 data-
base, these three categories account for 72% of all disease-
associated mutations.
Of the 286 pathological mutations, 257 (89.9%) are asso-
ciated with aniridia and 29 (10.1%) are associated with
other phenotypes, including isolated foveal hypoplasia,
microphthalmia and optic nerve defects.
The exon-by-exon distribution of mutation type for 257
aniridia-associated mutations is shown in Table 3. Of the
257 mutations, 100 (38.9%) are nonsense mutations, 34
(13.2%) are splice mutations, 65 (25.3%) are frame-shift-
ing insertions or deletions, 16 (6.2%) are in-frame
insertions or deletions, 30 (11.7%) are missense muta-
tions and 12 (4.7%) are run-on mutations (Figure 2b).
The proportion of missense mutations has decreased from
17.5% of all cases, to 11.7% of aniridia cases while muta-
tions that introduce a PTC (nonsense, splicing and frame-
shifting mutations) have increased from 72% of all cases
to 77% of aniridia cases.
Table 2: Exon-by-exon distribution of 286 disease-associated mutations in the PAX6 Allelic Variant Database
4 5 5a 6 7 8 9 10 11 12 13
Mutation type Total
N 0 6 0 9 7 2 42 31 41 6 3 0102
S 24041146590 36
F S 01 401 9 1 14 4 6 1 6 368
I F 030 1 3 0000000 16
M 3 1 3 5 1 4 3211062 50
R O 0000000000 1 4 14
T o t a l 5 4 0 5 5 92 23 13 22 72 22 41 9 2 8 6
N, nonsense mutation; S, splicing mutation; FS, frame-shifting insertion or deletion; IF, in-frame insertion or deletion; M, missense mutation; RO, 
run-on mutation. For a full definition of mutation types, see Table 1.
Distribution of different mutation types in the PAX6 Allelic Variant Database Figure 2
Distribution of different mutation types in the PAX6 Allelic Variant Database. (a) All disease-associated mutations in the data-
base; (b) mutations causing aniridia; (c) mutations causing non-aniridia phenotypes. Mutation definitions are given in Table 1.
(a) All phenotypes (b) Aniridia (c) Non-aniridia
Nonsense
Splicing
Frame-shift
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The exon-by-exon distribution of mutation type for 29
mutations in non-aniridia cases is shown in Table 4. Of
the 29 mutations, 2 (6.9%) are nonsense mutations, 2
(6.9%) are splice mutations, 3 (10.3%) are frame-shifting
insertions or deletions, 20 (69%) are missense mutations
and 2 (6.9%) are run-on mutations (Figure 2c). Missense
mutations account for over two-thirds of non-aniridia
phenotypes, while mutations that introduce a PTC are
much less common than in the database as a whole,
accounting for just 7 of the cases (24%).
This analysis shows that the aniridia phenotype is pre-
dominantly associated with mutations that introduce a
PTC, while non-aniridia phenotypes are predominantly
associated with missense mutations. The missense muta-
tions that cause non-aniridia phenotypes may do so by
generating hypomorphic proteins that are able to carry
out some but not all of the normal functions of PAX6,
such as the correct regulation of downstream target genes
[15,28]. The missense mutations that cause non-aniridia
phenotypes are predominantly located in the paired
domain (exons 5, 5a, 6 and 7, Table 4), suggesting that
partially impaired DNA binding may be a major mecha-
nism by which variant phenotypes arise [10,28,29]. Mis-
sense mutations can cause full-blown aniridia (Table 3),
presumably by creating PAX6 proteins with little or no
function [29]. Missense mutations associated with non-
aniridia phenotypes typically affect a subset of the ocular
tissues involved in full aniridia, such as the fovea, the
optic nerve or the iris [15,29].
Mutation hotspots in the PAX6 coding region
Nonsense mutations are the single most common muta-
tion type in aniridia patients (and in the whole database)
while missense mutations are the most common cause of
other phenotypes (Figure 2). Both nonsense and missense
mutations are caused by single nucleotide substitutions.
To learn more about how these mutations might arise, we
focussed on the distribution of CpG dinucleotides in the
PAX6 open reading frame, since CpG transitions are the
most common single nucleotide substitutions in the
human genome [30].
Table 3: Exon-by-exon distribution of 257 mutations that cause aniridia.
Exon 4 5 5a 6 7 8 9 10 11 12 13
Mutation type Total
N 0 6 0 9 7 2 32 31 41 6 2 0100
S 14041146490 34
F S 01 301 9 1 14 4 6 1 5 265
I F 030 1 3 0000000 16
M 3 1 1 0 1 0 0210021 30
R O 0000000000 1 2 12
T o t a l 4 3 7 0 5 51 93 03 22 62 11 81 5 2 5 7
N, nonsense mutation; S, splicing mutation; FS, frame-shifting insertion or deletion; IF, in-frame insertion or deletion; M, missense mutation; RO, 
run-on mutation. For a full definition of mutation types, see Table 1.
Table 4: Exon-by-exon distribution of 29 mutations that cause phenotypes other than aniridia.
Exon 4 5 5a 6 7 8 9 10 11 12 13
Mutation type Total
N 000001000102
S 100000001002
F S 010000000113
I F 000000000000
M 02543001041 20
R O 000000000022
T o t a l 13543101164 2 9
N, nonsense mutation; S, splicing mutation; FS, frame-shifting insertion or deletion; IF, in-frame insertion or deletion; M, missense mutation; RO, 
run-on mutation. For a full definition of mutation types, see Table 1.BMC Genetics 2005, 6:27 http://www.biomedcentral.com/1471-2156/6/27
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There are 45 CpG dinucleotides in the PAX6 coding region
(Figure 3). CpG deamination can give rise to two new
dinucleotides, TpG and CpA, depending on whether the
C>T conversion takes place on the forward strand or the
reverse strand. In the existing records, transitions at 10 of
the 45 CpG's have been reported (Figure 3, Table 5). Eight
CpG's have been mutated on one strand only, while two
have been mutated on both strands (Figure 3, Table 5). Of
the twelve changes, six cause nonsense mutations, five
cause missense mutations and one causes a synonymous
(neutral) substitution (Table 5).
Sense-strand deamination of CpG in an arginine codon
CGA creates a termination codon TGA. The PAX6 ORF
contains six CGA codons and all of these have been 'hit' at
least once to give nonsense mutations (Table 5). It is
Distribution of CpG dinucleotides in the PAX6 open reading frame Figure 3
Distribution of CpG dinucleotides in the PAX6 open reading frame. The PAX6 cDNA is represented as a horizontal rectangle 
with the different coding regions indicated: PB, paired box, LNK, linker region, HB, homeobox, PST, proline/serine/threonine-
rich region. Exon boundaries are indicated by vertical black lines. Exon numbers are shown beneath the cDNA, with the 
number of CpG's in brackets. Above the cDNA, each of the forty-five CpG dinucleotides in the PAX6 ORF is indicated by an 
arrow. Red arrows indicate the ten CpG's at which a nucleotide transition has occurred. Single-headed arrows indicate that 
the CpG deamination has occurred only on the forward strand (CpG > TpG). Double-headed arrows indicate that deamina-
tion has occurred both on the forward strand (CpG > TpG) and the reverse strand (CpG > CpA). Elongated red arrows indi-
cate those CpG's that have been hit more than once on the forward strand; the resultant mutation is shown together with the 
number (in brackets) of independent records in the database.
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noticeable that four CpG's in CGA codons in exons 8, 9,
10 and 11 (R203X, R240X, R261X and R317X) are a major
source of nonsense mutations (Table 5, Figure 3).
Together these four CpG's have been hit 60 times. These
hits all cause aniridia and account for 21% of all muta-
tions in the database and 59% of all nonsense mutations.
The observation that CpG's in exons 8, 9, 10 and 11 are a
major source of mutations can be explained at least in part
by the nucleotide composition and methylation status of
the genomic PAX6 gene. The 5' two-thirds of the gene
(from the promoter up to and including exon 7) are part
of an unusually large CpG island. This region of the gene
is very GC-rich and has a high frequency of CpG dinucle-
otides, most of which are unmethylated [31]. The last
third of the gene, containing exons 8–13, is more similar
to bulk genomic DNA, with a lower GC content. The fre-
quency of CpG dinucleotides is low, but those that exist
tend to be methylated, and methylation greatly increases
the frequency of spontaneous deamination of cytosine,
resulting in C>T transition [30,31]. Although only 13 of
the 45 CpG's are in exons 8–13 (Figure 3), these are in the
methylated region of the gene and are therefore much
more likely to be 'hit'.
C-terminal truncating mutations are not associated with 
more severe phenotypes
When the first PAX6 mutations were discovered in ani-
ridia patients, it quickly became apparent that mutations
that introduce a PTC into the open reading frame are com-
mon [3-6]. Speculation arose that mutations causing
translational termination after the homeodomain might
yield dominant negative forms of the PAX6 protein,
because truncated proteins containing only the DNA
binding domains could theoretically bind to target DNA
sequences without activating downstream genes and
hence interfere with the function of the normal PAX6 pro-
tein [21-23]. A variety of studies then demonstrated that
PAX6 proteins with C-terminal deletions do indeed have
dominant negative activity [21,22,24]. It might therefore
be expected that individuals with truncating mutations in
the PST domain would have very low levels of normal
PAX6 activity and this could result in a phenotype more
severe than, or markedly different from, individuals with
truncating mutations before the PST domain.
Mutations that introduce a PTC – nonsense mutations,
splicing mutations and frame-shifting insertions and
deletions – are scattered throughout the PAX6 open read-
ing frame (Table 2). We examined the database records for
evidence that late-terminating mutations (in the PST
domain) cause different phenotypes.
Of 151 mutations that introduce a PTC before the PST
domain (ie in the paired box, the linker region or the
homeobox), 150 are associated with aniridia or closely
related variants such as partial aniridia and iris hypopla-
sia. The remaining mutation is associated with optic nerve
hypoplasia [15].
Of 43 mutations that introduce a PTC into the PST
domain, 41 are associated with aniridia or closely related
phenotypic variants. The remaining two mutations are
associated with keratitis [16] and congenital cataracts
[11], phenotypes that clearly overlap with aniridia. There-
fore there is no evidence from the existing records that
truncating mutations in the PST domain are associated
with more severe phenotypes. Rather the data suggest that
truncating mutations are overwhelmingly associated with
aniridia regardless of their location in the gene.
Table 5: CpG transitions in the PAX6 open reading frame.
Nucleotide change Codon change Location Mutation type Reports
414G>A ACG>ACA (G18R) PD exon 5 Missense 1
494C>T CGA>TGA (R44X) PD exon 5 Nonsense 1
493G>A CGA>CAA (R44Q) PD exon 5 Missense 1
669C>T CGA>TGA (R103X) PD exon 6 Nonsense 3
744C>T CGC>TGC (R128C) PD exon 7 Missense 2
782C>T GAC>GAT (D140D) LNK exon 7 Neutral 1
969C>T CGA>TGA (R203X) LNK exon 8 Nonsense 15
984C>T CGG>TGG (R208W) LNK exon 8 Missense 1
985G>A CGG>CAG (R208Q) LNK exon 8 Missense 1
1080C>T CGA>TGA (R240X) HD exon 9 Nonsense 21
1143C>T CGA>TGA (R261X) HD exon 10 Nonsense 8
1311C>T CGA>TGA (R317X) PST exon 11 Nonsense 16
PD, paired domain; LNK, linker region; HD, homeodomain; PST, proline/serine/threonine-rich region. 'Reports' indicates how many times the 
mutation has been reported in the PAX6 Allelic Variant Database.BMC Genetics 2005, 6:27 http://www.biomedcentral.com/1471-2156/6/27
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How can the uniformity of patient phenotypes be recon-
ciled with experimental data demonstrating dominant
negative effects? One explanation is that the dominant
negative tests may not be physiologically relevant. The
experiments were performed on intronless cDNA con-
structs that terminate at an engineered stop codon and are
designed to produce large quantities of the truncated pro-
tein. In contrast the patients have PTCs that occur in the
context of an intact PAX6 gene. Once transcribed, PTC-
containing RNAs are likely to be degraded by nonsense-
mediated decay, a universal mechanism for preventing the
accumulation of truncated proteins [19,20]. Nonsense
mediated decay is inextricably linked to the synthesis,
processing, splicing and preliminary translation of
mRNAs derived from genomic genes [19,20]. Experimen-
tal cDNA constructs bypass these mechanisms to direct
the synthesis of high levels of proteins that would not nor-
mally be made in the cell [19].
We propose that the dominant negative tests do not accu-
rately reflect the in vivo consequence of truncating muta-
tions. The simplest interpretation of the phenotypic data
is that nonsense-mediated decay acts on most PTC-con-
taining RNAs to generate null alleles.
The existing data are entirely consistent with the hypothe-
sis that aniridia is a true haploinsufficiency phenotype,
caused by loss of function of one allele, either by deletion
or intragenic mutation. As mentioned previously, 77% of
all aniridia-associated mutations in the database result in
the introduction of a PTC. Therefore nonsense-mediated
decay may be the major mechanism by which PAX6 null
alleles are generated.
Absence of nonsense mutations at the 3' end of the PAX6 
coding region
Any hypothesis concerning the role of nonsense-mediated
decay must take into account the observation that it does
not act on the 3' extreme of a coding region. The surveil-
lance mechanism uses intron/exon boundaries as cues for
detection of PTCs and typically does not operate on the
last exon, or the last 50 bases of the penultimate exon
[19,32]. In the PAX6 gene, the zone that would escape
NMD would encompass the last 50 bp of exon 12 (from
base 1496 onwards) and the first 83 bases of exon 13 up
to the normal stop codon. This corresponds to the last 44
codons of the open reading frame (Figure 4). Truncating
mutations in this region of the PAX6 gene should not be
acted on by NMD and could theoretically generate domi-
nant negative forms of the protein. In experimental
assays, even a short reduction of 37 amino acids gave
potent dominant negative effects [21].
We inspected the database records to see what kinds of
mutations are present in the region that is predicted to
escape NMD (base 1496 onwards). Strikingly there are no
nonsense mutations in this region (Table 6). There are
four splicing mutations and five frame-shifting deletions,
but the predicted consequence of all of these is run-on
translation into the 3'UTR rather than introduction of a
PTC [5,14,33,35,36]. This is in sharp contrast to the 5' part
of exon 12 (up to base 1495), which contains a variety of
nonsense and frame-shifting mutations, all of which are
predicted to introduce a PTC (Table 6).
Thus there appears to be an absence of truncating muta-
tions in the part of the gene that is predicted to escape
NMD. To investigate this further, we looked at the distri-
bution of potential nonsense codons in the PAX6 coding
region. The PAX6  open reading frame contains 132
codons that could be mutated to stop codons by a single
base change. 102 nonsense mutations have been observed
in patients and these occur at 34 of the possible 132 sites
(Figure 4).
Fourteen of the potential nonsense codons lie within the
region predicted to escape NMD (base 1496 onwards) but
none of the resultant mutations has been observed to date
(Figure 4). Assuming a random distribution of all unique
nonsense mutations along the potential sites at which a
nonsense mutation could occur, the probability of
observing zero mutations in the non-surveillance zone is
0.012 calculated using Fisher's exact test (Figure 4). Thus
the absence of mutations in exon 13 and the last 50 bp of
exon 12 is unlikely to have arisen by chance.
As mentioned above, 9 different frame-shifting and splice
mutations have been reported in the region predicted to
escape NMD but none of these introduces a PTC. Rather
they are all predicted to cause run-on translation into the
3' untranslated region (Table 6) [5,7,14,33-37].
The phenotypes associated with run-on mutations are
well documented because the database contains details of
14 run-on mutations in which the normal termination
codon is altered to a coding codon. All of these patients
have aniridia or ocular defects within the aniridia spec-
trum such as iris hypoplasia, foveal hypoplasia, cataracts
and nystagmus.
Thus translation beyond the normal stop codon is consist-
ently associated with an aniridia-like phenotype, which
suggests that run-on mutations generate simple loss-of-
function alleles. Nonsense-mediated decay would not be
predicted to act on such alleles because there is no PTC;
therefore the proposed loss of function may result from
the addition of an extra peptide at the C-terminal end of
the PAX6 protein. The C-terminus of PAX6 is highly con-
served and appears to play a role in the stabilisation of
DNA binding by the homeodomain [12], so any disrup-BMC Genetics 2005, 6:27 http://www.biomedcentral.com/1471-2156/6/27
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tion to the structure of the C-terminal region could have
profound effects on the function of the PAX6 protein. It
should however be emphasised that the function of run-
on PAX6 proteins has not yet been tested; therefore
confirmation of the hypothesis that run-on proteins show
loss of function rather than dominant negative activity
awaits further experimentation.
The known PAX6 mutation spectrum is devoid of muta-
tions that introduce a PTC into the non-surveillance zone.
Such mutations must surely arise, yet clearly they are not
associated with aniridia. Given the evidence that even
short truncations of the PAX6 protein cause strong domi-
nant negative effects [21], we propose that termination
mutations in the last part of the gene cause phenotypes
significantly more severe than aniridia. These phenotypes
may resemble that of the only confirmed case of an
individual with a lethal compound heterozygous PAX6
mutation and may include anophthalmia, arhinia and
severe central nervous system defects [11].
Absence of nonsense mutations at the 3' end of the PAX6 coding region Figure 4
Absence of nonsense mutations at the 3' end of the PAX6 coding region. The PAX6 open reading frame is represented as a hor-
izontal rectangle; the untranslated regions are shown as thick black lines (not to scale). Exon boundaries are shown as vertical 
lines. PB, paired box; LNK, linker region; HB, homeobox; PST, PST region. Above the cDNA, thick double-headed arrows 
divide the coding region into two parts. Between bases 363–1495, nonsense-mediated decay is predicted to act on truncating 
mutations. The region from bases 1496–1628 is predicted to escape nonsense-mediated decay. The number of potential and 
observed nonsense mutations in the different zones of the coding region is shown in the lower part of the figure. No nonsense 
mutations have been observed in the region that escapes NMD, even though 14 codons could potentially give rise to nonsense 
mutations.
5 6 7 8 9 10 11 12 13 1-4
PB LNK HB PST
5a
NMD predicted
NMD not
predicted
Nonsense mutations Nonsense mutations Total potential
observed not observed nonsense mutations
Bases 316-1495 34 84 118
Bases 1496-1628 0 14 14
Total 34 98 132
363 1628 1496 1495BMC Genetics 2005, 6:27 http://www.biomedcentral.com/1471-2156/6/27
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Conclusion
We have reviewed the mutations in the PAX6 Allelic Vari-
ant Database. Aniridia is typically caused by mutations
that introduce a PTC, while non-aniridia phenotypes are
cause by missense mutations. Transitions at four CpG
dinucleotides in the methylated part of the gene make a
major contribution to the burden of PAX6  nonsense
mutations.
We have reasoned that nonsense-mediated decay acts on
PAX6 mutant alleles. Mutations that introduce a PTC are
consistently associated with aniridia or closely related
phenotypes, regardless of where they occur in the gene.
There is a statistically significant absence among the exist-
ing records of nonsense mutations in exon 13 and the last
50 bp of exon 12, where NMD would not be predicted to
act.
Mutations that introduce a termination codon before the
last 50 bases of exon 12 are likely to be acted on by non-
sense-mediated decay and are probably functionally null.
However mutations that introduce a termination codon
within the last 50 bases of exon 12, or within exon 13, are
likely to generate proteins with significant dominant neg-
ative activity. These mutations are not associated with ani-
ridia and may cause very severe phenotypes that have not
yet been ascertained. The effect of NMD on phenotypic
severity has been experimentally demonstrated for SOX10
and MPZ, mutations of which cause neurochristopathies
and myelinopathies respectively [38]. In SOX10 and MPZ,
truncating mutations at the 3' end of the open reading
frame escape NMD and generate dominant negative
proteins that cause much more severe phenotypes than
more 5' mutations [38].
The mutation spectrum of a gene can yield important
insights into the molecular mechanisms that act on
mutant alleles and the phenotypes that are likely to be
associated with mutations in that gene.
Methods
PAX6 cDNA reference sequence and numbering
The PAX6 cDNA sequence used in this paper is taken from
the PAX6 Allelic Variant Database [25]. The coding region
runs from base 363 (in exon 4) to base 1628 (in exon 13).
The PST region extends from base 1169 to base 1628.
PAX6 mutations and phenotypes
Data on the PAX6 mutation spectrum were collected from
the PAX6 Allelic Variant Database. Only pathological
mutations were considered, either within the coding
region of the gene (bases 363–1628) or within the
consensus splice acceptor and donor sequences of introns.
Coding region polymorphisms and intronic changes out-
side the splice consensus sequences were not considered.
Each mutation was placed into one of six categories (non-
Table 6: Outcome of potential PTC-creating mutation in exons 12 and 13.
Mutation Location Consequence of mutation Type NMD predicted
1399delC Exon 12 PTC at TGA starting at base 1453 FSD Yes
1410delC Exon 12 PTC at TGA starting at base 1453 FSD Yes
1420C>G (S353X) Exon 12 Immediate PTC N Yes
1424C>G (Y354X) Exon 12 Immediate PTC N Yes
1426ins5 Exon 12 PTC at TGA starting at base 1469 FSI Yes
1452delG Exon 12 PTC at TGA starting at base 1453 FSD Yes
1469T>G (Y369X) Exon 12 Immediate PTC N Yes
1513del4 Exon 12 Run-on into 3'UTR FSD No
1520delGGinsT Exon 12 Run-on into 3'UTR FSD No
1545G>C Exon 12 Run-on into 3'UTR S No
IVS12+1del3 Intron 12 Run-on into 3'UTR S No
IVS12+4A>G Intron 12 Run-on into 3'UTR S No
IVS12+5G>A Intron 12 Run-on into 3'UTR S No
1562delT Exon 13 Run-on into 3'UTR FSD No
1601delT Exon 13 Run-on into 3'UTR FSD No
1615del10 Exon 13 Run-on into 3'UTR FSD No
This table shows the outcome of every known PAX6 mutation from the start of exon 12 onwards that could potentially introduce a premature 
termination codon. Mutations up to and including nucleotide 1495 are within the region in which nonsense-mediated decay is predicted to occur, 
while mutations from nucleotide 1496 onwards are predicted to escape nonsense-mediated decay. IVS, intervening sequence (intron); FSD, frame-
shifting deletion; FSI, frame shifting insertion; N, nonsense mutation; S, splice mutation. PTC, premature termination codon; 3' UTR, 3' untranslated 
region.BMC Genetics 2005, 6:27 http://www.biomedcentral.com/1471-2156/6/27
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sense, splicing, frame-shifting insertion/deletion, in-
frame insertion/deletion, missense and run-on – see Table
1 for definitions). There are twelve compound mutations
in the database, each apparently involving more than one
mutational event, such as an insertion and a deletion.
These were categorised according to the final consequence
of the mutation. For example the compound mutation
495delAinsCAT has a net effect of inserting two bases and
is therefore categorised as a frame-shifting mutation.
Distribution of CpG dinucleotides and potential 
termination codons
The Mutability program determines the number and dis-
tribution of CpG dinucleotides and the number and dis-
tribution of potential nonsense and missense mutations
arising from single nucleotide substitutions in a cDNA
sequence. It is freely available through the PAX6 Allelic
Variant Database web site [26]. We used the Mutability
program to determine the location of CpG dinucleotides
in the PAX6 open reading frame, and to determine the
total number of codons that could potentially be mutated
to a stop codon by a single nucleotide change [26]. The
analysis was carried out on the complete coding region of
PAX6, including exon 5a. For exons 4 and 13, which con-
tain the initiation and termination codons respectively,
only the coding DNA was considered.
Fisher's exact test
The number of observed nonsense mutations in the cod-
ing region was obtained from the PAX6 Allelic Variant
Database. The number of nonsense mutations that were
not observed was calculated by subtracting the number of
observed mutations from the number of potential muta-
tions (calculated using the Mutability program, above).
The 'non-surveillance zone' of the coding region, in which
RNA surveillance should not act was defined as the coding
region of exon 13 and the last 50 bp of exon 12, ie from
nucleotide c.1496 onwards. Application of Fisher's exact
test to the 2 × 2 table shown in Figure 4 [34, 84, 0, 1] gives
a one-tailed probability of p = 0.012, which is significant
beyond the 5% level and allows rejection of the null
hypothesis that the observed nonsense mutations are ran-
domly distributed throughout the coding region. The
Fisher's exact test calculation was carried out using the
tool at http://www.matforsk.no/ola/fisher.htm[27]
Abbreviations
NMD, nonsense-mediated decay; ORF, open reading
frame; PTC; premature termination codon.
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